Back HIV/AIDS

HIV / AIDS

HIV R4P: Model Suggests More Frequent Truvada PrEP Needed for Vaginal vs Anal Sex

Tenofovir reaches lower levels in vaginal and cervical tissue compared with rectal tissue, helping to explain why pre-exposure prophylaxis (PrEP) did not protect women as much as gay and bisexual men in clinical trials, and suggesting that women having vaginal sex may need to take PrEP more often than people having anal sex, researchers reported at the HIV Research for Prevention meeting this week in Cape Town.

alt

Second European PrEP Study Closed Early Due to High Effectiveness

In an extraordinary development, a second European scientific trial of pre-exposure prophylaxis (PrEP) has had its randomized phase closed early due to high effectiveness, just two weeks after the UK PROUD trial did exactly the same thing. All participants assigned to receive placebo in the IPERGAY trial will be offered intermittent Truvada PrEP.

alt

HIV R4P: HIV Prevention Requires Supporting and Respecting Key Affected Populations

Supporting, protecting, and involving key populations heavily impacted by HIV -- including gay and bisexual men, sex workers, and people who inject drugs -- is a critical aspect of HIV prevention. Advances in biomedical prevention must be developed in collaboration with and made available to the people who need them most, according to several presentations at the HIV Research for Prevention meeting taking place this week in Cape Town.

alt

HIV Research for Prevention Conference Features Advances in Vaccines, Microbicides, PrEP

The first HIV Research for Prevention -- or HIV R4P -- conference takes place this week in Cape Town, bringing together more than 1300 leading researchers, policymakers, and advocates working on interventions such as HIV vaccines, microbicides, antiretroviral treatment as prevention (TasP), and new forms of pre-exposure prophylaxis (PrEP). The conference incorporates the previously separate HIV vaccine and microbicide meetings as biomedical prevention technologies have converged.

alt

HIV and Hepatitis C Highlights from AIDS 2014

Latest Positive Pulse Newsletter

Paul Sax from Harvard Medical School and Mark Sulkowski from Johns Hopkins School of Medicine discuss highlights from this summer's International AIDS Conference, the largest and most comprehensive global meeting on the medical, public health, and social aspects of HIV and AIDS.

Highlights of this overview include the HIV cascade of care, developments in antiretroviral therapy, pre-exposure prophylaxis (PrEP) and other HIV prevention news, and new hepatitis C treatment for people with HIV/HCV coinfection.

10/22/14

alt

IDWeek 2014: Acute Retroviral Syndrome Linked to Higher HIV Levels in Blood, Gut and Brain

People with acute or very recent HIV infection who experience the flu-like symptoms of acute retroviral syndrome (ARS) have higher levels of HIV RNA and proviral DNA in their blood, colon, and brain tissue, indicating more active viral replication, as well as higher levels of certain inflammatory biomarkers researchers reported at IDWeek 2014 this month in Philadelphia.

alt

IDWeek 2014: Earlier Treatment, NNRTI Use Predict Slower HIV Rebound After Stopping ART

HIV viral load usually begins to rise again within 4 to 8 weeks after stopping antiretroviral therapy (ART), though starting treatment earlier in the course of infection and using a non-nucleoside reverse transcriptase inhibitor (NNRTI) may delay viral rebound, according to study findings presented at IDWeek 2014 last week in Philadelphia.

alt